Skip to main content
Top

Cellular Oncology

Issue 5/2016

Content (7 Articles)

Original Paper

MGMT DNA repair gene promoter/enhancer haplotypes alter transcription factor binding and gene expression

Meixiang Xu, Courtney E. Cross, Jordan T. Speidel, Sherif Z. Abdel-Rahman

Original Paper

Hypoxia-inducible microRNA-488 regulates apoptosis by targeting Bim in osteosarcoma

Chusong Zhou, Wei Tan, Hai Lv, Fei Gao, Jin Sun

Original Paper

Ovarian cancer-derived ascitic fluids induce a senescence-dependent pro-cancerogenic phenotype in normal peritoneal mesothelial cells

Justyna Mikuła-Pietrasik, Paweł Uruski, Kinga Matuszkiewicz, Sebastian Szubert, Rafał Moszyński, Dariusz Szpurek, Stefan Sajdak, Andrzej Tykarski, Krzysztof Książek

Report

A network including PU.1, Vav1 and miR-142-3p sustains ATRA-induced differentiation of acute promyelocytic leukemia cells - a short report

Silvia Grassilli, Ervin Nika, Elisabetta Lambertini, Federica Brugnoli, Roberta Piva, Silvano Capitani, Valeria Bertagnolo

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine